Why the study?
Does MTHFR C677T/A1298C polymorphism predict adverse reactions after methotrexate in patients with hematological malignancies?
Population
Patients with hematological malignancies (17 studies)
Comparison
Presence of MTHFR C677T/A1298C genetic… vs Absence of MTHFR C677T/A1298C genetic polymorphism
Design
Meta-analysis
Authors
Loading...
MTHFR genotyping should not inform methotrexate management in hematological malignancies; meta-analysis reinforces lack of predictive value while leaving minor hepatotoxicity link open.
Does MTHFR C677T/A1298C polymorphism predict adverse reactions after methotrexate in patients with hematological malignancies?
MTHFR C677T/A1298C polymorphism does not appear to be a reliable indicator for predicting methotrexate-related side effects in hematological malignancies.
Yao et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: